No 10Y consistency score yet for revenue — the window needs more comparable quarters.
Valuation vs own 10Y history: P/S N/A · No P/S — trailing revenue unavailable or non-positive.
Annualized revenue (TTM) · by quarter, last 18
Quarterly YoY revenue growth vs the 20% line
P/S multiple vs its 10Y median
The latest delayed quote for Estrella Immunopharma, Inc. (ESLA) stock was $0.47 as of Oct 6, 2026, 10:34 AM EDT, up 6.34% from the previous close.
Longer view (total return, dividends reinvested): past 12 months -66.2% · 3-year avg -45.8%/yr · 5-year avg -46.3%/yr
Estrella Immunopharma, Inc. is an early-stage biopharmaceutical enterprise focused on creating T-cell therapies for various blood cancers and solid tumors, with its primary activities centered in the United States.
Biotechnology · EmeryVille, CA
Next Earnings Date
Dec 2, 2026
57 days away
EPS Estimate
-0.08
Revenue Est.
N/A
Last Quarter Results
EPS
$-0.05
vs Estimate
$-0.05
Revenue
$0.00
vs Estimate
$0.00
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR | Compare |
|---|---|---|---|---|---|---|---|
| 1ESLA | $19.96M | $0.47 | +6.34% | -66.24% | -46.34% | N/A | N/A |
| 2ACTU | $19.59M | $0.82 | -6.40% | -87.34% | N/A | N/A | vs ESLA |
| 3MODD | $20.54M | $2.52 | +9.57% | -88.60% | N/A | N/A | vs ESLA |
| 4COSM | $19.15M | $0.35 | +1.76% | -67.82% | -68.41% | -45.52% | vs ESLA |
| 5NEUP | $18.92M | $3.50 | +1.45% | -82.12% | N/A | N/A | vs ESLA |
| 6MRKR | $17.51M | $1.05 | -0.94% | +11.06% | -42.13% | -33.25% | vs ESLA |
forward FY estimate
N/A
Consensus Rating
Based on 1 analyst
Average Price Target
$12.00
+2464.7% upside
Low
$12.00
Current
$0.47
High
$12.00
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $-0.08 | $-0.08 | $-0.08 | 1 |
| Quarter ending Dec 2026 | $-0.07 | $-0.07 | $-0.07 | 1 |
| Quarter ending Mar 2027 | $-0.12 | $-0.12 | $-0.12 | 1 |
| Quarter ending Jun 2027 | $-0.11 | $-0.11 | $-0.11 | 1 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2026 | $-0.25 | $-0.25 | $-0.25 | 1 |
| FY 2027 | $-0.32 | $-0.32 | $-0.32 | 1 |
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $0.00 | $0.00 | $0.00 | 0 |
| Quarter ending Dec 2026 | $0.00 | $0.00 | $0.00 | 0 |
| Quarter ending Mar 2027 | $0.00 | $0.00 | $0.00 | 0 |
| Quarter ending Jun 2027 | $0.00 | $0.00 | $0.00 | 0 |
Annual
| Period | Low |
|---|
Source: FMP Analyst Consensus Estimates. Forward P/E is unavailable for the current price and estimate observations.
| Avg |
|---|
| High |
|---|
| # Analysts |
|---|
| FY 2026 | $0.00 | $0.00 | $0.00 | 0 |
| FY 2027 | $0.00 | $0.00 | $0.00 | 0 |
